Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic ...

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings ...

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a ...

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President ...

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...

Steven R. Sarkisian Jr., MD, ABO, presented data from an FDA clinical trial of a travopost intracameral implant. The iDose TR (Glaukos) is indicated for reduction of intraocular pressure (IOP) using a ...

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.